Biocon delivered a strong start to FY27 with a sharp rise in earnings. The company's Q1 profit jumped four times year-on-year, supported by steady biosimilars demand. Revenue also increased, reflecting healthy growth across its key business segments.
The latest developments highlight drug approvals, pharma investments, and healthcare innovation shaping the global and Indian pharmaceutical landscape
GLP-1 drug demand is reshaping global pharma economics, as Eli Lilly raised its 2026 sales in its obesity and diabetes portfolio
Cancer patients facing rare and aggressive pancreatic tumors now gain renewed hope as the USFDA grants approval for Eli Lilly’s olomorasib
Alembic Pharma started FY27 with a strong first quarter. The company reported healthy growth in profit and revenue. Its performance was supported by new product launches, volume growth, and steady execution across key markets.
Quarterly Earnings took the spotlight after Pfizer reported better-than-expected second-quarter results. However, the company made it clear that its focus extends beyond one strong quarter.
Drug approvals and pharma manufacturing continue to shape the pharmaceutical landscape as new research, regulatory developments, and financial results drive industry momentum
Ebola treatment efforts intensify as the WHO accelerates clinical trials in response to the outbreak in the Democratic Republic of the Congo
Biocon has entered the US eye drug market with the commercial launch of Yesafili, its aflibercept biosimilar to Eylea.
Retatrutide Early Access has started for a limited group of patients before its expected FDA approval. Eli Lilly has launched an expanded access program for eligible adults with severe obesity.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")